Patents by Inventor Michael A. Lochrie

Michael A. Lochrie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AAV vectors for gene delivery to the lung
    Publication number: 20060018841
    Abstract: Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue.
    Type: Application
    Filed: June 2, 2005
    Publication date: January 26, 2006
    Applicant: Avigen, Inc.
    Inventors: Alejandra Arbetman, Michael Lochrie
  • High affinity TGFbeta nucleic acid ligands and inhibitors
    Publication number: 20040258656
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Application
    Filed: March 30, 2004
    Publication date: December 23, 2004
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • High affinity TGF&bgr; nucleic acid ligands and inhibitors
    Patent number: 6713616
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: March 30, 2004
    Assignee: Gilead Sciences, Inc.
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • Methods for producing stocks of recombinant AAV virions
    Publication number: 20030134404
    Abstract: Methods for removing empty capsids from stocks of AAV virions comprising mixtures of empty and packaged capsids are described. The methods entail heating and adjusting the pH value of the stock, optionally in the presence of one or more chemical destabilizing agents.
    Type: Application
    Filed: November 26, 2002
    Publication date: July 17, 2003
    Inventors: Michael A. Lochrie, Peter Colosi
  • High affinity TGFbeta nucleic acid ligands and inhibitors
    Publication number: 20030064943
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Application
    Filed: February 23, 2001
    Publication date: April 3, 2003
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
    Publication number: 20030049644
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Application
    Filed: February 4, 2002
    Publication date: March 13, 2003
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold
  • High affinity TGf&bgr; nucleic acid ligands and inhibitors
    Patent number: 6346611
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: February 12, 2002
    Assignee: Gilead Sciences, Inc.
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
    Patent number: 6344321
    Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: February 5, 2002
    Assignee: Gilead Sciences, Inc.
    Inventors: Ross Rabin, Michael Lochrie, Nebojsa Janjic, Larry Gold
  • High affinity HIV-1 gag nucleic acid ligands
    Patent number: 5726017
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to HIV-1 GAG, Included in the invention are specific RNA ligands to HIV-1 GAG identified by the SELEX method, Also included are RNA ligands that inhibit the function of HIV-1 GAG.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: March 10, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Michael A. Lochrie, Larry Gold